TMDX
Transmedics Group Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
Market Cap: 2.75 Billion
Primary Exchange: NASDAQ
Website: transmedics.com
Shares Outstanding: 32.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.5192527234835285
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
Ethical Flags
Longest drawdown: 385 trading days
From: 2019-05-22 To: 2020-11-27
Lowest Point:
TransMedics, Inc. (TMDX) CEO Waleed Hassanein on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-06-11 16:46:08:000
TransMedics, Inc. (TMDX) Q1 2019 Results Conference Call June 11, 2019 04:30 PM ET Company Participants Greg Chodaczek - IR Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants David Lewis - Morgan St… read more...
TransMedics, Inc. (TMDX) CEO Waleed Hassanein on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-06-11 16:46:08:000
TransMedics, Inc. (TMDX) Q1 2019 Results Conference Call June 11, 2019 04:30 PM ET Company Participants Greg Chodaczek - IR Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants David Lewis - Morgan St… read more...
TransMedics Group reports Q1 results
via: SeekingAlpha at 2019-06-11 12:10:20:000
TransMedics Group (NASDAQ: TMDX ): Q1 Net loss of $6.9M. More news on: TransMedics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|